肺移植术中支持策略优化：限制性体外循环与基于标准的ECMO对早期神经结局的影响
Posted inClinical Updates Neurology Respiratory

Optimizing Intraoperative Support in Lung Transplantation: Impact of Restrictive CPB Versus Criteria-Based ECMO on Early Neurologic Outcomes

This study evaluates the shift from restrictive cardiopulmonary bypass (CPB) to criteria-based extracorporeal membrane oxygenation (ECMO) in lung transplantation, revealing a reduction in early major neurologic complications and ischemic strokes despite increased intraoperative blood loss and graft dysfunction.
放化疗后不可切除Ⅲ期非小细胞肺癌巩固治疗：benmelstobart 联用或不联用 anlotinib 的 R-ALPS 试验解读
Posted inClinical Updates Oncology Respiratory

Evaluating Benmelstobart With or Without Anlotinib as Consolidation Therapy After Chemoradiotherapy in Unresectable Stage III NSCLC: Insights from the R-ALPS Trial

The R-ALPS randomized trial confirms that benmelstobart improves progression-free survival in unresectable stage III NSCLC patients post-chemoradiotherapy, while adding anlotinib does not significantly enhance efficacy and raises severe toxicity risks.
EGFR 突变晚期 NSCLC 新突破：Izalontamab Brengitecan 优于含铂化疗
Posted inClinical Updates Oncology Respiratory

Izalontamab Brengitecan Shows Promising Efficacy Over Platinum Chemotherapy in EGFR-Mutated NSCLC Post-Third-Generation EGFR TKI Progression

The PANKU-Lung01 phase 3 trial demonstrates izalontamab brengitecan significantly extends progression-free survival compared to platinum-based chemotherapy in EGFR-mutated advanced non-squamous NSCLC after failure of third-generation EGFR TKIs, with manageable safety profile.